Proactive Investors - Run By Investors For Investors

Propanc welcomes founding member back to scientific advisory board

Ralf Brandt returns to the board after temporarily stepping down in 2018
empty boardroom
PRP is designed to target tumors in pancreatic, ovarian and colorectal cancers

Propanc Biopharma Inc (OTCMKTS:PPCB) welcomed the co-inventor of its flagship drug back to its scientific advisory board, the company announced Monday.

Ralf Brandt, who helped the metastatic cancer treatment company develop its drug PRP, returns to the board after resigning in 2018.

He spent seven years on the board before stepping down to oversee the merger of vivoPharm, an oncology discovery company he co-founded.

READ: Propanc CEO looks to harness power of pancreatic enzymes in cancer fight

“We are pleased to welcome Dr. Brandt back to our scientific advisory board,” CEO James Nathanielsz said. “He played a pivotal role in advising the company, which enabled us to complete our preclinical development activities for the advancement of PRP to a first-in-human study in cancer patients. We look forward to his continued support and guidance, as we now focus our attention towards preparing for the planned clinical trial and progressing PRP through early stage clinical development.”

PRP is a treatment designed to target tumors in pancreatic, ovarian and colorectal cancers. Metastatic cancer, which Propanc focuses on, occurs when cancer cells spread to other areas of the body.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full PPCB profile View Profile

Propanc Biopharma Inc Timeline

Related Articles

antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue
dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use